Managing advanced skin cancer remains a significant clinical challenge for oncologists. A recent real-world study published in The Oncologist evaluated the effectiveness of melanoma brain metastases treatment using stereotactic radiosurgery (SRS) combined with concurrent ipilimumab and nivolumab (ipi/nivo). This research specifically investigated how previous systemic therapy exposure influences survival and intracranial disease control.

Melanoma Brain Metastases Treatment and Prior Therapy

Researchers found that patients who were naive to immune checkpoint inhibitors (ICI) showed significantly better survival. For example, ICI-naive patients achieved a median overall survival of 50.5 months. In contrast, those with prior ICI exposure only reached 17.6 months. Consequently, prior therapy status is a crucial predictor of success in the clinical setting. Moreover, intracranial progression-free survival (iPFS) was notably longer in the treatment-naive group, reaching 15.1 months compared to just 5.9 months for those previously treated. Furthermore, this trend suggests that early integration of combined modalities may yield the best results.

Safety and Efficacy of SRS with Combined Immunotherapy

Combining SRS with ipi/nivo provides durable intracranial control with a manageable safety profile. Specifically, at the 24-month mark, the local progression rate remained low at 11%. Additionally, the incidence of radionecrosis was only 7%, and leptomeningeal disease occurred in just 4% of cases. However, patients with a high disease burden, defined as 11 or more SRS-treated lesions, faced a significantly higher risk of treatment failure. Therefore, clinicians should carefully assess the number of metastases when planning therapeutic interventions.

Predictors of Long-term Survival

The study utilized multivariable analysis to identify several critical prognostic factors. Aside from prior ICI use, previous treatment with BRAF/MEK inhibitors also predicted worse overall survival. On the other hand, a higher Graded Prognostic Assessment (GPA) score favored better outcomes. Because these high-risk subgroups represent a significant portion of the patient population, researchers emphasize the need for intensified or novel treatment strategies. Ultimately, these findings support a personalized approach to managing metastatic melanoma.

FAQ

Does previous immunotherapy affect melanoma brain metastases treatment success?

Yes, the study demonstrated that patients with prior immune checkpoint inhibitor exposure had a median survival of 17.6 months, compared to 50.5 months in treatment-naive patients.

What is the risk of radiation-induced complications in this study?

The combination of SRS and ipi/nivo was relatively well-tolerated, with radionecrosis occurring in only 7% of patients and leptomeningeal disease in 4%.

Which patients are considered high-risk in this combined treatment model?

Patients who have 11 or more brain lesions, a low GPA score, or previous exposure to targeted therapies like BRAF/MEK inhibitors are considered at higher risk for poorer outcomes.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.

References

1. Messing I et al. Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy. Oncologist. 2026 Feb 15. doi: undefined. PMID: 41693007.


2. Kleber TJ et al. Outcomes of patients with melanoma brain metastases treated with ipilimumab and nivolumab with or without upfront comprehensive stereotactic radiosurgery. Neurooncol Adv. 2026 Jan 7;8(1):vdaf276.


3. Tawbi HA et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018 Aug 23;379(8):722-730.